4-氯-6-甲氧基7-氟-喹啉-3-甲腈 | 622369-40-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-6-甲氧基7-氟-喹啉-3-甲腈
• 中文别名: 4-氯-7-氟-6-甲氧基喹啉-3-甲腈；4-氯-6-甲氧基-7-氟-喹啉-3-甲腈；4-氯-7-氟-6-甲氧基-3-喹啉甲腈；4-氯-7-氟-6-甲氧基喹啉-3-腈
• 英文名称: 4-chloro-6-methoxy-7-fluoro-quinoline-3-carbonitrile
• 英文别名: 4-chloro-7-fluoro-6-methoxy-3-quinolinecarbonitrile；7-Fluoro-4-chloro-6-methoxy-quinoline-3-carbonitrile；4-chloro-7-fluoro-6-methoxyquinoline-3-carbonitrile；7-fluoro-4-chloro-6-methoxyquinoline-3-carbonitrile
• CAS: 622369-40-8
• 化学式: C₁₁H₆ClFN₂O
• 分子量: 236.633
• InChiKey: PNVRUIFACIJUKH-UHFFFAOYSA-N

物化性质

• 沸点：
  394.8±37.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  45.9
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  4-氯-6-甲氧基7-氟-喹啉-3-甲腈 在 吡啶盐酸盐 、 sodium hydride 作用下， 以 乙二醇乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 4-[(2,4-二氯-5-甲氧基苯基)氨基]-6-甲氧基-7-[2-(1-甲基-4-哌啶基)乙氧基]-3-喹啉甲腈
  参考文献：
  名称：

  7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as Dual Inhibitors of Src and Abl Kinases

  摘要：

  We previously reported that several 7-alkoxy-4-phenylamino-3-quinolinecarbonitriles were potent inhibitors of Src kinase activity. We disclose here a new highly efficient and versatile route to these compounds, which are also potent inhibitors of Abl kinase.

  DOI：

  10.1021/jm0499458
• 作为产物：
  描述：

  3-氟-4-甲氧基苯胺 在 三氯氧磷 作用下， 以 甲苯 为溶剂， 反应 5.0h， 生成 4-氯-6-甲氧基7-氟-喹啉-3-甲腈
  参考文献：
  名称：

  7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as Dual Inhibitors of Src and Abl Kinases

  摘要：

  We previously reported that several 7-alkoxy-4-phenylamino-3-quinolinecarbonitriles were potent inhibitors of Src kinase activity. We disclose here a new highly efficient and versatile route to these compounds, which are also potent inhibitors of Abl kinase.

  DOI：

  10.1021/jm0499458

文献信息

• [EN] 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML)<br/>[FR] 4-ANILINO-3-QUINOLINECARBONITRILES DESTINES AU TRAITEMENT DE LEUCEMIE MYELOGENE CHRONIQUE (CML)
  申请人：WYETH CORP

  公开号：WO2005047259A1

  公开（公告）日：2005-05-26

  Compounds of the formula (I): wherein: n is an integer from 0-3; X is N, CH; R is alkyl of 1 to 3 carbon atoms; R' is 2,4-diCl, 5-OMe in para, ortho, or meta position; 2,4-diCl in para position; 3,4,5­tri-OMe in para position; 2-Cl, 5-OMe in para position; 2-Me, 5-OMe in para position; 2,4-di-Me in para position; 2,4-diMe-5-OMe in para position; 2,4-diCl, 5-OEt in para position; and R2 is alkyl of 1 to 3 carbon atoms, and pharmaceutically acceptable salts thereof.

  式(I)的化合物：其中：n是0-3之间的整数；X是N，CH；R是1至3个碳原子的烷基；R'是对位、邻位或间位的2,4-二氯，5-甲氧基；对位的2,4-二氯；对位的3,4,5-三甲氧基；对位的2-氯，5-甲氧基；对位的2-甲基，5-甲氧基；对位的2,4-二甲基；对位的2,4-二甲基-5-甲氧基；对位的2,4-二氯，5-乙氧基；以及R2是1至3个碳原子的烷基，及其药用可接受的盐。
• 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors
  申请人：Mayer Scott Christian

  公开号：US20090264427A1

  公开（公告）日：2009-10-22

  Imidazole-substituted 4-anilino-3-cyanoquinolines are described, which selectively inhibit IFGR kinase activity and are useful for treating disorders associated with IGFR kinases.

  描述了咪唑取代的4-苯胺基-3-氰基喹啉类化合物，其选择性抑制IGFR激酶活性，并可用于治疗与IGFR激酶相关的疾病。
• Process for the preparation of 7-substituted-3 quinolinecarbonitriles
  申请人：Wyeth Holdings Corporation

  公开号：US20030212276A1

  公开（公告）日：2003-11-13

  There is provided a process for the preparation of 7-substituted-3-quinolinecarbonitriles and intermediates useful in a process to prepare 7-substituted-3-quinolinecarbonitriles and pharmaceutically acceptable salts is described. Where 7-fluoro-4-oxo-1,4-dihydro-3-quinolinecarbonitrile is converted in three steps to 7-substituted-3-quinolinecarbonitriles which inhibit the action of certain protein kinases and are useful in the treatment of cancer.

  提供了一种制备7-取代-3-喹啉羰基腈和中间体的方法，该中间体在制备7-取代-3-喹啉羰基腈和药用可接受盐的过程中有用。将7-氟-4-氧代-1,4-二氢-3-喹啉羰基腈转化为7-取代-3-喹啉羰基腈，经过三个步骤，这些化合物抑制某些蛋白激酶的作用，并在癌症治疗中有用。
• 3-Quinolinecarbonitrile protein kinase inhibitors
  申请人：Berger Maarten Dan

  公开号：US20050187247A1

  公开（公告）日：2005-08-25

  This invention provides a compound of Formula 1 where Ar, X, R 1 , R 2 , R 3 , and R 4 are defined herein, or a pharmaceutically acceptable salt thereof useful in the prevention or inhibition of diseases associated with the Ras/Raf/MEK signaling cascade in a mammal, such as neoplasms, strokes, osteoporosis, cancer, rheumatoid arthritis, inflammatory disease, polycystic kidney disease, and colonic polyps, and methods of making the compounds of formula 1 and intermediates.

  该发明提供了一种化合物，其化学式为1，其中Ar、X、R1、R2、R3和R4的定义如下，或其药用盐，在哺乳动物体内用于预防或抑制与Ras/Raf/MEK信号级联相关的疾病，如肿瘤、中风、骨质疏松症、癌症、类风湿性关节炎、炎症性疾病、多囊性肾病和结肠息肉，以及制备化合物1和中间体的方法。
• 一种治疗白血病药物用中间体的制备方法
  申请人：邹永旗

  公开号：CN109134366A

  公开（公告）日：2019-01-04

  本发明属于化学药物技术领域，具体涉及一种治疗白血病药物用中间体的制备方法。本发明将N‑[3‑(三乙氧硅烷基)丙基]‑4,5‑双氢咪唑负载到氧化硅上，然后与1,4‑丁磺酸内酯、三氟乙酸反应生成硅胶负载的酸性离子液体；作为酸性催化剂催化4‑氯‑6‑甲氧基7‑氟‑喹啉‑3‑甲腈和2,4‑二氯‑5‑甲氧基苯胺反应生成治疗白血病药物用中间体4‑(2,4‑二氯‑5‑甲氧基苯氨)‑7‑氟‑6‑甲氧基喹啉‑3‑腈，收率高达90.2%，且工艺绿色环保；硅胶负载的酸性离子液体可通过简单过滤从反应体系中去除，且能够催化多种底物发生芳香族亲核取代反应。